Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson’s disease
نویسندگان
چکیده
منابع مشابه
Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.
Comment. Possessing an APOE ε4 allele is the most important genetic risk factor yet identified for sporadic AD and also significantly lowers onset age. It is therefore striking that despite their young age at onset, only 2 of our 10 biparietal patients were ε4-positive. While we believe that a lack of association between biparietal AD (or posterior cortical atrophy AD) and APOE ε4 genotype has ...
متن کاملClinical heterogeneity of the LRRK2 G2019S mutation.
BACKGROUND Several pathogenic mutations have been reported in the leucine-rich repeat kinase 2 gene (LRRK2) that cause parkinsonism. The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease. OBJECTIVE To observe the clinical heterogeneity presented by LRRK2 kinase mutation carriers. DESIGN, SETTIN...
متن کاملGait alterations in healthy carriers of the LRRK2 G2019S mutation.
To test for an association between the LRRK2-G2019S mutation and gait, we studied 52 first-degree relatives of patients with Parkinson's disease (PD) who carry this mutation. An accelerometer quantified gait during usual-walking, fast-walking, and dual-tasking. Noncarriers (n = 27) and carriers (n = 25) were similar with respect to age, gender, height, and gait speed during all conditions. Duri...
متن کاملOlfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?
OBJECTIVE Olfactory impairment is a potential marker for impending phenoconversion to Parkinson disease (PD) that may precede the development of disease by several years. Because of low specificity, it may be of greater predictive value in those with genetic mutations and its potential as a marker for developing LRRK2 PD should be evaluated. METHODS We examined olfactory identification in 126...
متن کاملValidity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease.
The G2019S mutation in the LRRK2 gene, the most common known cause of Parkinson's disease (PD), will soon be widely available as a molecular clinical test for PD. The objective of this study was to assess performance characteristics of G2019S as a clinical test for PD in the setting of typical movement disorder clinics in the United States. Subjects included 1,518 sequentially recruited PD pati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry
سال: 2018
ISSN: 0022-3050,1468-330X
DOI: 10.1136/jnnp-2018-319364